Drug Sequencing in Melanoma
Jeffrey A. Sosman, MD, from the Vanderbilt-Ingram Cancer Center, discusses drug sequencing for patients with melanoma at the 11th Annual International Congress on Targeted Therapies in Cancer.
at the 11th Annual International Congress on Targeted Therapies in Cancer.
Jeffrey A. Sosman, MD, Professor of Medicine, Director, Melanoma and Tumor Immunotherpay Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, discusses drug sequencing for patients with melanoma
In the practical sense, the questions regarding drug sequencing and selection are very important, Sosman says. Many in the oncology community believe that some patients will have a better chance at long term durable response if they are treated with immunotherapy first.
Clinical Pearls
Sometimes, when a patient treated with targeted therapies relapses, they do so with fairly aggressive disease and may not respond to immunotherapy. Sosman says that treatment for melanoma remains a judgment call for an individual patient and oncologist.
- There remains a need to determine the best drug sequence and selection in melanoma
- Some patients who relapse do so with fairly aggressive disease and may not respond to immunotherapy at that time
- In certain groups of patients, it would be better to treat with immunotherapy first
Management of Immune-Related Toxicities in Melanoma Has Improved Over Time
April 24th 2024During a Case-Based Roundtable® event, Evan J. Lipson, MD, discussed with participants how their experience with immunotherapy toxicities has changed over time in the first article of a 2-part series.
Read More
